Summary by Moomoo AI
Adial Pharmaceuticals, Inc. (Adial), a Delaware-based pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on January 12, 2024. The registration statement, identified as Form S-3, includes a prospectus for the potential sale of various securities, which may comprise common stock, preferred stock, debt securities, warrants, and units. The company has not specified the total amount of securities to be offered or the timing of any sales, indicating that offerings will occur from time to time based on market conditions. The registration statement outlines the terms under which the securities may be offered, the use of proceeds, and the company's indemnification obligations to directors and officers. Adial has made provisions for the securities to be sold through underwriters, dealers, or directly to the public, with the possibility of book-entry or global securities issuance. The registration statement also includes financial statements audited by Marcum LLP and legal opinions by Blank Rome LLP.
